Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Blog Posts
BTN Blog Top Card Health
January 17, 2020
Jennifer Bright with the Innovation and Value Initiative recently wrote for Morning Consult that the U.S. is “engaged in the challenging but important conversation about how to assess the value of pharmaceuticals.” …
BTN Blog Top Card Health
January 16, 2020
The 340B Drug Discount Program is in the spotlight with the release of a new report from the Government Accountability Office (GAO) calling attention to oversight of the program designed to help vulnerable patients gain…
Veterans Are Under
December 18, 2020
Rick Starrs, CEO of NAVREF When it comes to clinical research trials, America leads the world in providing patients with access to the latest, state-of-the-art care. However, an under-represented…
Press Releases
December 12, 2019
Former Congressman Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the U.S. Senate confirmed Dr. Stephen Hahn to serve as the next commissioner of the Food and Drug Administration: “The Food and Drug Administration plays a…
December 10, 2019
Exclusion of biologics provisions in revised USMCA sets dangerous precedent for future trade talks, including with China Puts American jobs, intellectual property and leadership in medical innovation at risk WASHINGTON – BIO President and CEO Jim Greenwood released the following statement in…
Letters, Comments & Testimony
January 10, 2020
January 7, 2020 Re: Docket No. FDA–2019-N-3453: Promoting Effective Drug Development Programs: Opportunities and Priorities for the Food and Drug Administration's Office of New Drugs Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA)…
January 10, 2020
January 4, 2020 Re: Docket No. FDA–2019-N-5157: 2019 Public Meeting on Center for Drug Evaluation and Research Standard Core Sets: Clinical Outcome Assessments and Endpoints Grant Program. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks Food and Drug Administration (FDA or…
December 17, 2019
On December 16, 2019, the Biotechnology Innovation Organization (BIO) provided comments on the Food and Drug Administration’s (FDA’s) Notice to Public of Website Location of CDRH Fiscal Year 2020 Proposed Guidance Development; In Vitro Diagnostic (IVD) Device Studies – Frequently Asked…
Patient-Take-Action
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.